Bristol Converts APOE4 to APOE3 in Blood Cells
Bristol researchers converted APOE4 to the lower-risk APOE3 variant in immune blood cells from people with Alzheimer's disease, but the experiment does not establish safety or benefit in patients.
Bristol Researchers Convert APOE4 to APOE3 in Blood Cells
On September 28, a University of Bristol team reported converting the APOE4 gene variant to APOE3 in immune blood cells obtained from people with Alzheimer's disease. So far, the result comes from a cell experiment.
The APOE gene encodes a protein that helps the brain remove beta-amyloid, a protein that accumulates in Alzheimer's disease and forms characteristic plaques. APOE4 and APOE3 encode different versions of the APOE protein: the APOE4 version helps remove beta-amyloid less effectively. APOE4 is considered the strongest known genetic risk factor for the disease, while APOE3 is associated with lower risk. This led the researchers to test whether they could convert APOE4 to APOE3.
According to the university, editing had little effect on the rest of the cells' DNA. That observation comes from the cell experiment; the safety and therapeutic effects of this intervention in patients still need to be tested.
For future clinical use, the authors are considering delivery through the bloodstream. A key issue is the blood-brain barrier, a layer of cells between blood and brain tissue. The university explains that it prevents some Alzheimer's treatments from reaching all brain regions. The Bristol team edits immune cells that already circulate in the blood. However, the source does not report whether the edited cells reach the relevant brain regions or benefit patients.
The Eternal Search glossary page on this topic provides context for comparing this approach with others. For example, the experimental gene therapy LX1001 used a viral vector to deliver the code for another variant, APOE2, into the fluid surrounding the brain and spinal cord. This added a new copy of the gene to the body. The Bristol experiment changed the existing APOE4 in blood cells.
The approaches also differ in how far testing has progressed. The LX1001 phase 1/2 study with 15 participants is listed as completed in ClinicalTrials.gov, the international clinical trials registry. The supplied material contains no efficacy results. When reading gene therapy news, it therefore helps to establish which cells were changed, how the intervention was delivered, and what results came from cells or from people. Bristol has shown a gene variant conversion in patients' cells; its effect on the course of the disease remains unknown.
Open the related Eternal Search page
Sources
[1] bristol.ac.uk
[2] t.me
The Bristol experiment gives a concrete, side-by-side illustration for the Eternal Search gene therapy glossary page: the same news item contains two named approaches (direct gene editing in blood cells versus viral vector delivery into cerebrospinal fluid) that differ in mechanism, making the glossary page a natural destination for readers who want to distinguish between them rather than treat the label as a single method.